Is Glofitomab a Matchmaker Drug for Follicular Lymphoma?

Glofitomab is a CD3 CD20 bi specific or T cell engager and so I always like to think about this is that you know remember these patients have seen a lot of retuximab right so their CD20 has been perturbed a lot. The question truly is going to be is can you come off therapy and relapse refractory large olemboma and then if you do have a relapse can you reuse the drugs to reengage the immune system after giving it a break and still get the same ability to get a complete remission? That's not been quite answered here but really you can see the opportunity for disease control over time with glofitom